Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,025 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria.
Hide M, Park HS, Igarashi A, Ye YM, Kim TB, Yagami A, Roh J, Lee JH, Chinuki Y, Youn SW, Lee SK, Inomata N, Choi JH, Fukunaga A, Wang J, Matsushima S, Greenberg S, Khalil S. Hide M, et al. Among authors: igarashi a. J Dermatol Sci. 2017 Jul;87(1):70-78. doi: 10.1016/j.jdermsci.2017.03.009. Epub 2017 Mar 21. J Dermatol Sci. 2017. PMID: 28366435 Free article. Clinical Trial.
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
Asahina A, Etoh T, Igarashi A, Imafuku S, Saeki H, Shibasaki Y, Tomochika Y, Toyoizumi S, Nagaoka M, Ohtsuki M; study investigators. Asahina A, et al. Among authors: igarashi a. J Dermatol. 2016 Aug;43(8):869-80. doi: 10.1111/1346-8138.13258. Epub 2016 Feb 15. J Dermatol. 2016. PMID: 26875540 Free PMC article. Clinical Trial.
Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.
Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, Galus R, Etoh T, Mihara R, Yoshida H, Stewart J, Kabashima K; XCIMA Study Group. Ruzicka T, et al. N Engl J Med. 2017 Mar 2;376(9):826-835. doi: 10.1056/NEJMoa1606490. N Engl J Med. 2017. PMID: 28249150 Free article. Clinical Trial.
Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study.
Hide M, Igarashi A, Yagami A, Chinuki Y, Inomata N, Fukunaga A, Kaiser G, Wang J, Matsushima S, Greenberg S, Khalil S. Hide M, et al. Among authors: igarashi a. Allergol Int. 2018 Apr;67(2):243-252. doi: 10.1016/j.alit.2017.10.001. Epub 2017 Nov 1. Allergol Int. 2018. PMID: 29102514 Free article. Clinical Trial.
Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials.
Katoh N, Kataoka Y, Saeki H, Hide M, Kabashima K, Etoh T, Igarashi A, Imafuku S, Kawashima M, Ohtsuki M, Fujita H, Arima K, Takagi H, Chen Z, Shumel B, Ardeleanu M. Katoh N, et al. Among authors: igarashi a. Br J Dermatol. 2020 Jul;183(1):39-51. doi: 10.1111/bjd.18565. Epub 2019 Nov 28. Br J Dermatol. 2020. PMID: 31564057 Free PMC article.
Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
Imafuku S, Nakagawa H, Igarashi A, Morita A, Okubo Y, Sano S, Tada Y, Nemoto O, Rozzo SJ, Kawamura M, Ohtsuki M. Imafuku S, et al. Among authors: igarashi a. J Dermatol. 2021 Jun;48(6):844-852. doi: 10.1111/1346-8138.15763. Epub 2021 Feb 1. J Dermatol. 2021. PMID: 33523513 Free PMC article. Clinical Trial.
1,025 results